GlobeNewswire: OmniComm Systems Inc. Contains the last 10 of 145 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:05:31ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2020/03/16/2001103/0/en/Anju-Software-announces-appointment-of-new-CMO-to-support-and-sustain-rapid-growth.html?f=22&fvtc=4&fvtv=15812Anju Software announces appointment of new CMO to support and sustain rapid growth2020-03-16T13:00:00Z<![CDATA[TEMPE, Ariz., March 16, 2020 (GLOBE NEWSWIRE) -- Anju Software announced today that Bill Leander has joined its executive leadership team as Chief Marketing Officer (CMO). As CMO, Mr. Leander’s focus will be on further accelerating growth by strengthening Anju’s marketing capabilities, advancing product management disciplines, and communicating the proven power of products to the life sciences market. To quote Bill, “Anju has a wealth of technology and products that meet mission-critical needs of the organizations we support. The breadth of our products and ability to craft tailored solutions for clients is truly impressive. I look forward to serving as Anju’s ‘Chief Storyteller’ to share with the world our innovations and successes of our clients.”]]>https://www.globenewswire.com/news-release/2019/12/16/1960987/0/en/Sofpromed-CRO-Adopts-OmniComm-s-TrialMaster-as-EDC-Solution-for-Clinical-Trials-in-Oncology.html?f=22&fvtc=4&fvtv=15812Sofpromed CRO Adopts OmniComm’s TrialMaster® as EDC Solution for Clinical Trials in Oncology2019-12-16T14:00:00Z<![CDATA[Spain-based, oncology-focused CRO will use TrialMaster EDC to support clinical data management services for sponsors in the oncology sector, particularly in phase I-IV cancer trials Spain-based, oncology-focused CRO will use TrialMaster EDC to support clinical data management services for sponsors in the oncology sector, particularly in phase I-IV cancer trials]]>https://www.globenewswire.com/news-release/2019/12/02/1954809/0/en/FGK-Clinical-Research-Signs-Five-Year-Agreement-with-OmniComm-Systems-for-Multiple-eClinical-Products.html?f=22&fvtc=4&fvtv=15812FGK Clinical Research Signs Five-Year Agreement with OmniComm Systems for Multiple eClinical Products2019-12-02T14:00:00Z<![CDATA[FORT LAUDERDALE, Fla., Dec. 02, 2019 (GLOBE NEWSWIRE) -- FGK Clinical Research GmbH (FGK), a European, full-service contract research organization has entered into a multi-year partnership with OmniComm Systems, Inc., an Anju Software company and a leading global provider of patient-centric, clinical data management technology. Under the terms of the agreement, FGK will use TrialMaster® electronic data capture (EDC), IRTMaster (web-based self-service clinical supply management and randomization), and Acuity Analytics (data visualization and risk-based monitoring) along with other related products/services to supplement FGK’s clinical trial operational and data management services to pharmaceutical, biotechnology and medical device companies.]]>https://www.globenewswire.com/news-release/2019/11/25/1952293/0/en/OmniComm-Systems-Releases-IRTMaster-Version-5-2-a-Customizable-Interactive-Response-Technology-System-for-Streamlined-Clinical-Trial-and-Supply-Management.html?f=22&fvtc=4&fvtv=15812OmniComm Systems Releases IRTMaster Version 5.2, a Customizable Interactive Response Technology System for Streamlined Clinical Trial and Supply Management2019-11-25T22:29:58Z<![CDATA[OmniComm’s IRTMaster Features Configurable, Pre-Validated Modules to Accelerate Trial Development]]>https://www.globenewswire.com/news-release/2019/09/27/1922039/0/en/OmniComm-Systems-and-snapIoT-to-Showcase-Virtual-Decentralized-Trials-Technology-at-SCDM-2019.html?f=22&fvtc=4&fvtv=15812OmniComm Systems and snapIoT to Showcase Virtual/Decentralized Trials Technology at SCDM 20192019-09-27T18:59:55Z<![CDATA[FORT LAUDERDALE, Sept. 27, 2019 (GLOBE NEWSWIRE) -- Virtual or decentralized clinical trials — named one of the year’s top trends in digital health technology by Forbes magazine — will claim center stage at the annual conference of the Society of Clinical Data Management (SCDM), Sept. 29-Oct. 2, in Baltimore, MD. At the event, OmniComm Systems and snapIoT will demonstrate how their respective eClinical solutions enable virtual/decentralized trials. The two companies will show how ePRO, eCOA, eConsent and other innovations can facilitate and simplify real-time data integration during virtual/decentralized clinical trials.]]>https://www.globenewswire.com/news-release/2019/09/18/1917432/0/en/Anju-Completes-Merger-With-OmniComm-Systems.html?f=22&fvtc=4&fvtv=15812Anju Completes Merger With OmniComm Systems2019-09-18T13:23:18Z<![CDATA[FORT LAUDERDALE, Fla., Sept. 18, 2019 (GLOBE NEWSWIRE) -- OmniComm Systems Inc. announced today that Anju Software Inc. has completed the acquisition of OmniComm Systems, Inc. (OTCQX: OMCM), a leading strategic software solutions provider to the life sciences industry. Under the terms of the agreement, OmniComm is now a wholly owned subsidiary of Anju, a provider of data software and services to life science companies, contract research organizations and medical device manufacturers. Anju is a privately owned, Abry Partners portfolio company.]]>https://www.globenewswire.com/news-release/2019/07/31/1894811/0/en/Global-Biopharmaceutical-Company-Signs-Five-Year-Agreement-to-Use-Technology-Suite-From-OmniComm-Systems-for-Rare-Disease-Studies.html?f=22&fvtc=4&fvtv=15812Global Biopharmaceutical Company Signs Five-Year Agreement to Use Technology Suite From OmniComm Systems for Rare Disease Studies 2019-07-31T13:30:00Z<![CDATA[Fort Lauderdale, Fla., July 31, 2019 (GLOBE NEWSWIRE) -- Treatments for rare diseases represent approximately one-third of the drugs now under development globally, according to a new academic study. OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology, continues to expand its role in that therapeutic area with a new agreement. An international biopharmaceutical company focused on rare diseases has signed a five-year contract to use OmniComm’s suite of eClinical solutions to build and manage global Phase III and Phase IV studies targeting rare pediatric diseases.]]>https://www.globenewswire.com/news-release/2019/07/16/1883375/0/en/OmniComm-Systems-to-be-acquired-by-Anju-Software.html?f=22&fvtc=4&fvtv=15812OmniComm Systems to be acquired by Anju Software2019-07-16T13:00:00Z<![CDATA[FORT LAUDERDALE, Fla., July 16, 2019 (GLOBE NEWSWIRE) -- OmniComm Systems, Inc. (OTCQX: OMCM) (“OmniComm”), a leading strategic software solutions provider to the life sciences industry, announced today that it has entered into a merger agreement with Anju Software, Inc. (“Anju”). Under the terms of the agreement, OmniComm will become a wholly owned subsidiary of Anju. Upon closing, shares of OmniComm common stock will be cancelled and automatically converted into the right to receive $0.41032 per share, without interest, representing an 58% premium to the closing price on July 15, 2019.]]>https://www.globenewswire.com/news-release/2019/07/09/1880252/0/en/Symbio-Signs-Five-Year-Agreement-for-OmniComm-s-TrialMaster-EDC.html?f=22&fvtc=4&fvtv=15812Symbio Signs Five-Year Agreement for OmniComm’s TrialMaster® EDC2019-07-09T13:30:00Z<![CDATA[FORT LAUDERDALE, Fla., July 09, 2019 (GLOBE NEWSWIRE) -- Symbio LLC, a client-focused, full-service clinical research organization (CRO), has signed a five-year contract with OmniComm Systems, Inc. (OTCQX: OMCM), a leading global provider of clinical data management technology. Under the agreement, Symbio will use OmniComm’s TrialMaster version 5 to develop and manage clinical study databases.]]>https://www.globenewswire.com/news-release/2019/05/24/1849191/0/zh-hans/OmniComm-Systems%E6%88%90%E5%8A%9F%E4%B8%BE%E5%8A%9E%E4%BA%9A%E6%B4%B2%E5%88%9B%E6%96%B0%E8%AE%BA%E5%9D%9B.html?f=22&fvtc=4&fvtv=15812OmniComm Systems成功举办亚洲创新论坛2019-05-24T13:11:12Z<![CDATA[佛罗里达州劳德代尔堡, May 24, 2019 (GLOBE NEWSWIRE) -- 全新药物创新,以人为本的电子临床(eClinical)解决方案和制药研究的最新趋势,成为亚洲创新论坛的首要议程,本次论坛是由全球领先的临床数据管理技术提供商OmniComm Systems,Inc(OTCQX:OMCM)主办的首届客户峰会。由Tri-I Biotech合办的上海活动吸引了远超预期的众多参与者和演讲者。]]>